Cantor Fitzgerald analyst Louise Chen maintains $AbbVie (ABBV.US)$ with a buy rating, and adjusts the target price from $200 to $240.
According to TipRanks data, the analyst has a success rate of 41.3% and a total average return of -9.5% over the past year.
Furthermore, according to the comprehensive report, the opinions of $AbbVie (ABBV.US)$'s main analysts recently are as follows:
AbbVie's recent report of robust results for Q3 and the subsequent increase in revenue guidance for 2024 contribute to a positive outlook for the company as the year concludes. This optimistic financial trajectory is reflected in the enhanced earnings per share forecast for 2025. Despite this, the assessment of the company's long-term growth prospects in relation to its present market value retains a stance of neutrality.
Following AbbVie's Q3 report, which surpassed expectations and raised future guidance, there is an increase in confidence regarding the company's growth outlook. The revised projections are primarily due to anticipated higher sales of Rinvoq/Skyrizi, though this is somewhat balanced by reduced expectations for aesthetics and Humira sales.
AbbVie has delivered another commendable quarter. The outlook on the shares remains positive, underscored by promising pipeline developments and robust commercial traction looking towards 2025.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
坎托·菲茨杰拉德分析師Louise Chen維持$艾伯維公司 (ABBV.US)$買入評級，並將目標價從200美元上調至240美元。
根據TipRanks數據顯示，該分析師近一年總勝率為41.3%，總平均回報率為-9.5%。
此外，綜合報道，$艾伯維公司 (ABBV.US)$近期主要分析師觀點如下：
艾伯維公司最近公佈的第三季度強勁業績報告以及對2024年營收指引的增加，有助於在年終時爲公司展示積極的前景。這種樂觀的財務發展軌跡體現在2025年每股收益預測的提升上。儘管如此，在評估公司與當前市值相關的長期增長前景方面，仍保持中立立場。
在艾伯維公司第三季度業績報告之後，超出預期並提高未來指引，人們對公司的增長前景更加有信心。修正後的預測主要是由於預計Rinvoq/Skyrizi銷售增加，儘管這在一定程度上被對美容和Humira銷售預期降低所平衡。
艾伯維公司又交出了令人稱讚的季度業績。股票前景仍然樂觀，主要受到有望開發的潛在項目和力強勁的商業拖車在2025年展望上的支撐。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
